Incyte Corp. | Mutual Funds
Mutual Funds that own Incyte Corp.
Vanguard Health Care Fund
10,657,473
5.01%
1,190,500
1.57%
06/30/2018
American Funds New Perspective Fund
4,885,500
2.29%
-1,500,200
0.44%
06/30/2018
Vanguard Total Stock Market Index Fund
4,526,365
2.13%
18,404
0.05%
07/31/2018
Vanguard Mid Cap Index Fund
4,276,142
2%
33,605
0.31%
07/31/2018
BB Biotech AG
3,698,322
1.74%
30,000
6.58%
03/31/2018
Vanguard 500 Index Fund
3,186,958
1.5%
4,645
0.05%
07/31/2018
iShares Nasdaq Biotechnology ETF
2,450,616
1.14%
-32,046
1.85%
09/06/2018
T Rowe Price Health Sciences Fund
2,421,428
1.13%
149,000
1.4%
06/30/2018
Government Pension Fund - Global (The)
2,203,206
1.04%
533,972
0.02%
12/31/2017
T Rowe Price Mid Cap Growth Fund
2,000,000
0.94%
750,000
0.45%
06/30/2018
| Address |
1801 Augustine Cut-Off
Wilmington Delaware 19803
United States
|
|
Employees
|
- |
| Website |
http://www.incyte.com |
| Updated |
07/08/2019 |
| Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. |
